Camargo Pharmaceutical Services Names Jim Beach Chief Operating Officer

Camargo Pharmaceutical Services Names Jim Beach Chief Operating Officer

CINCINNATI--(BUSINESS WIRE)--Jim Beach, a veteran health care executive with broad experience in operations, R&D, marketing and sales, has been named chief operating officer for Camargo Pharmaceutical Services, a leading drug development organization specializing in the 505(b)(2) approval pathway.

"Camargo clients will benefit from his market research knowledge as well as his ability to build teams that can accomplish goals with speed and efficiency."
"Jim's history and accomplishments prove his business acumen and leadership skills," said Ken Phelps, Camargo president and CEO. "Camargo clients will benefit from his market research knowledge as well as his ability to build teams that can accomplish goals with speed and efficiency."

Prior to joining Camargo, Beach had been vice president of marketing and product management for scientific products for Cardinal Health; vice president of market insights and a member of the U.S. management board for Ethicon Endo-Surgery; and leader of the global product company program for GE Healthcare.

Beach is a certified GE Six Sigma quality leader and an expert at streamlining business processes. While at Cardinal Health, he increased business unit profitability by 8 percent through product life cycle management, mix optimization and new product launches.

"Jim will add great depth to our leadership team and enable Camargo to grow while strengthening our core values and culture of excellence," Phelps said. "I am confident his work in building our processes and structure will pay off in even greater efficiencies for our clients."

About Camargo Pharmaceutical Services

Camargo Pharmaceutical Services is your full-service drug development partner specializing in the 505(b)(2) process. Before development even begins, we verify profit potential by working with your team to develop a comprehensive program and timeline complete with important milestones and cost objectives. We manage every facet of the plan throughout your development continuum, from feasibility assessments, formulation and testing the drug product, to conducting preclinical and clinical studies, to final submission. Connect with Camargo on LinkedIn, the President's blog or visit www.camargopharma.com for more information.

Contacts

SCORR Marketing
Lea Studer, 308-237-5567
[email protected]

Suggested Articles

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.